Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (46)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by KHOURY, M. J.
Right arrow Articles by HOLTZMAN, N. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KHOURY, M. J.
Right arrow Articles by HOLTZMAN, N. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology Vol. 126, No. 1: 136-143
Copyright © 1987 by The Johns Hopkins University School of Hygiene and Public Health


research-article

ON THE ABILITY OF BIRTH DEFECTS MONITORING TO DETECT NEW TERATOGENS

MUIN J. KHOURY1, and NEIL A. HOLTZMAN2

1Department of Epidemiology, The Johns Hopkins University School of Hygiene and Public Health Baltimore, MD
2The Johns Hopkins University School of Medicine Baltimore, MD

Reprint requests to Dr. Muin J. Khoury at current address: Center for Environmental Health, Centers for Disease Control, Atlanta, GA 30333.

Recent concerns have been raised about the ability of birth defects monitoring programs to detect increases in the incidence of birth defects following the introduction of new teratogens. The authors illustrate how most monitoring programs in the United States and Europe are limited in their ability to detect new teratogens because of a combination of parameters: the small population size, the low population frequency of exposure to the new teratogen, the weakness of many suspected teratogens (measured in terms of relative risk R), the low background rate, and the etiologic heterogeneity in the measured defects. In a system that monitors 25,000 births per year, it can be shown that although a new teratogen such as thalidomlde (R = 175) can lead to a significant increase in the number of observed cases in 1–2 weeks of monitoring, even strong teratogens such as valproic add and isotretbtoin (R = 20–25) require more than 20 years of monitoring to show a significant Increase in the number of cases because of low exposure frequency. Also, most mild to moderate teratogens (R = 2–5) can be totally missed. To improve the ability of birth defects monitoring programs to detect new teratogens, it Is suggested that surveillance systems ought to examine subsegments of the population with maximal exposure potential, classify birth defects into more etiotogically homogeneous groups, and expand the sample size of the monitored population.

birth defects; epklemiologlc monitoring; teratogens


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Arch DermatolHome page
B. R. Reed
Dermatologic Drugs, Pregnancy, and Lactation: A Conservative Guide
Arch Dermatol, July 1, 1997; 133(7): 894 - 898.
[Abstract] [PDF]


Home page
Science CommunicationHome page
D. Indyk and D. A. Rier
Grassroots AIDS Knowledge: Implications for the Boundaries of Science and Collective Action
Science Communication, September 1, 1993; 15(1): 3 - 43.
[Abstract]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.